Skip to main content
SpringerLink
Log in

Immunsuppressiva und Zytostatika

  • Chapter
Wirkstoffe in der dermatologischen Therapie

  • 65 Accesses

Zusammenfassung

Immunsuppressiva und Zytostatika gehören zu den eingreifendsten Substanzen der modernen Pharmakologie. Ihr Einsatz muß deshalb besonders überlegt werden und sollte nur den lebensbedrohenden oder die Lebensqualität entscheidend beeinträchtigenden Krankheitsbildern vorbehalten bleiben. Dazu gehören in erster Linie Autoimmunerkrankungen, bösartige Neubildungen der Haut und ihrer Anhangsgebilde sowie schwere Formen anderer Erkrankungen wie z.B. Psoriasis oder Ekzem.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Moschella SL (1977) Chemotherapy used in dermatology. Cutis 19: 603

    PubMed  CAS  Google Scholar 

  2. Gutterman JV, Mavligit GM, Gottlieb JA, Burgess MA, McBride CM, Einhorn, L, Freireich E, Hersch EM (1974) Chemoimmunotherapy of disseminated malignant melanoma with dimethyl triazeno imidazol carboxamide and Bacillus Calmette Guerin. N Engl J Med 291: 592 (1974)

    Google Scholar 

  3. Veronesi U, Beretta G (1979) Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immuntherapy as an adjuvant to surgery in malignant melanoma (trial 6): Preliminary report. In: Bonadonna G, Methe G, Salmon SE (eds) Recent Results in Cancer Research Vol 68. Springer, Berlin Heidelberg New York, p 375 - 379

    Google Scholar 

  4. Landthaler M, Hohenleutner U, Braun-Falco O (1984) Adjuvante Therapie maligner Melanome im Stadium I. Ztrbl Haut Gschlkr 149: 1192

    Google Scholar 

  5. Wacker D, Runne U, Dancygier H, Hauk H (1982) Klinische Warnzeichen vor DTIC-bedingten Zwischenfällen. Z Hautkr 57: 501 - 502

    Google Scholar 

  6. Frosch PJ, Czarnetzki BM, Macher E, Grundmann E, Gottschalk J (1979) Hepatic failure in a patient treated with dacarbazine ( DTIC) for malignant melanoma. J Cancer Res Clin Oncol 95: 281–286

    Google Scholar 

  7. Balda BR, Bassermann R (1980) Dacarbazin-(DTIC-)Therapie und Budd-Chiari-Syndrom. Münch Med Wochenschr 122: 792–794

    CAS  Google Scholar 

  8. Zachariae H (1983) Zytostatika-Behandlung der Psoriasis. In: Braun-Falco O, Burg G (Hrsg) Fortschr prakt Dermatol Venerol, Bd 10. Springer, Berlin Heidelberg New York Tokyo, S 63–66

    Google Scholar 

  9. Weinstein G, Frost P (1971) Methotrexate for psoriasis - a new therapeutic schedule. Arch Dermatol 103: 33–38

    Article  PubMed  CAS  Google Scholar 

  10. Luderschmidt Chr, Balda BR (1983) Morbus Reiter. Erfolgreiche Kombinations-Chemotherapie mit Methotrexat, Etretinat und Prednisolon. Münch Med Wochenschr 125: 936–940

    Google Scholar 

  11. Klein E, Stoll HL, Milgrom H, Traenkle HL, Graham X (1966) Tumors of the skin. VI. Study of effect of local administration of 5-fluorouracil in basal cell carcinoma. J Invest Dermatol 47: 22

    Article  CAS  Google Scholar 

  12. Ott F, Storck H (1971) 5-Fluorouracil als Lokaltherapeutikum bei Präkanzerosen und Karzinomen der Haut. Schweiz Med Wochenschr 101: 1243

    Google Scholar 

  13. Frick E, Angstwurm H, Strauss G (1974) Immunsuppressive Therapie der multiplen Sklerose. 3. Mitteilung: Eigene Behandlungsergebnisse mit Azathioprine und Antilymphozytenglobulin. Münch Med Wochenschr 166: 2105

    Google Scholar 

  14. Malkinson FD (1982) Colchicine: new uses of an old drug. Arch Dermatol 118: 453–456

    Article  PubMed  CAS  Google Scholar 

  15. Aram H (1983) Colchicine in dermatologic therapy. Int J Dermatol 22: 566–569

    Article  PubMed  CAS  Google Scholar 

  16. Braun-Falco O, Ring J, Rieber P, Riethmüller G (1983) Erworbenes Immundefekt-Syndrom (AIDS). Kasuistik und Diagnostik. Münch Med Wochenschr 125: 1135–1139

    Google Scholar 

  17. Munkvad M, Genner J, Staberg B, Kongsholm H (1983) Locally injected bleomycin in the treatment of warts. Dermatologica 167: 86–89

    Article  PubMed  CAS  Google Scholar 

  18. Jones EC, Epinette WW, Hackney VL, Menendez L, Frost P (1975) Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol 65: 537–542

    Article  PubMed  CAS  Google Scholar 

  19. Brendel W, Seifert J, Ring J (1975) Die klinische Anwendung von Antilymphozytenglobulin. Münch Med Wochenschr 117: 1363

    Google Scholar 

  20. Ring J, Seifert J, Lob G, Coulin K, Angstwurm H, Frick E, Brass B, Mertin J, Backmund H, Brendel W (1974) Intensive immunosuppression in the treatment of multiple sclerosis. Lancet 2: 1093

    Article  PubMed  CAS  Google Scholar 

  21. Ring J, Seifert J, Lob G, Hopf U, Land W, Brendel W (1974) Allergic reactions to a horse-globulin therapy and their prevention by induction of immunological tolerance. Allergol Immunopathol (Madr) 2: 3

    Google Scholar 

  22. Borel JF, Feurer C, Magnee C, Stahelin H (1977) Effects of the antilymphocytic peptide cyclosporin A in animals. Immunology 32: 1017

    PubMed  CAS  Google Scholar 

  23. Bunjes D, Hardt C, Röllinghoff M, Wagner H (1981) Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur J Immunol 11: 657

    Article  PubMed  CAS  Google Scholar 

  24. Calne RY, White DJG, Thirn S, Evans DB, McMaster P, Dunn DC, Craddock GN, Pentlow BD, Rolles K (1978) Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2: 1323–1327

    Article  PubMed  CAS  Google Scholar 

  25. Müller W, Graf U (1981) Die Behandlung der Psoriasis-Arthritis mit Cyclosporin A, einem neuen Immunsuppressivum. Schweiz Med Wochenschr 111: 408–413

    PubMed  Google Scholar 

  26. Penneys NS, Eaglstein WH, Frost P (1976) Management of pemphigus with gold compounds: A long-term follow-up report. Arch Dermatol 112: 185–187

    Google Scholar 

  27. Schumacher K, Maerker-Aizer G, Preuss R (1975) Effect of D-penicillamine on lymphocyte function. Arzneimittelforsch 25: 603–606

    PubMed  CAS  Google Scholar 

  28. Nimni ME, Bavetta LA (1965) Collagen defect induced by penicillamine. Science 150: 905–907

    Article  PubMed  CAS  Google Scholar 

  29. Medsger TA, Rodnan G (1983) Beneficial effect of D-penicillamine therapy in progressive systemic sclerosis. In: Kukita A, Seiji M (eds) Prog. XVI. Int. Congr. Dermatol. University of Tokyo Press, Tokyo, pp 317–319

    Google Scholar 

  30. Luderschmidt Chr (1980) Behandlung der Sklerodermie mit Spironolakton. Hautarzt 31: 571

    Google Scholar 

  31. Nazarro-Porro M, Passi S, Zina G, Bernengo A, Breathnach A, Gallagher S, Morpurgo G (1980) Effect of azelaic acid on human malignant melanoma. Lancet 1: 1109–1111

    Article  Google Scholar 

  32. Braun-Falco O (1976) Neuere Aspekte zur Pathogenese der Hauterscheinungen bei Psoriasis vulgaris. Hautarzt 27: 363

    PubMed  CAS  Google Scholar 

  33. Rhode B (1978) Psoriasis-Kompendium. Perimed Verlag, Erlangen

    Google Scholar 

  34. Weber G, Neidhardt M, Frey H, Galle K, Geiger A (1981) Treatment of psoriasis with bromocriptin. Arch Dermatol Res 271: 437 - 439

    Article  PubMed  CAS  Google Scholar 

  35. Weber G, Neugebauer D, Neidhardt M (1983) Zur Behandlung der Psoriasis mit Hemmern des Wachstumshormons und durch Aktivierung der ß-Rezeptoren. Hautarzt [Suppl VI] 34: 316 - 318

    Google Scholar 

  36. Zürcher K, Krebs A (1980) Hautnebenwirkungen interner Arzneimittel. Karger, Basel

    Google Scholar 

  37. Holzmann H, Morsches B, Krapp R, Hoffmann G, Oertel GW (1972) Zur Therapie der Psoriasis mit Dehydroepiandrosteron-Oenanthat. Z Haut Geschl Kr 47: 99

    CAS  Google Scholar 

  38. Unna PG (1916) Cignolin als Heilmittel der Psoriasis. Dermatol Wochenschr 62: 116–126

    Google Scholar 

  39. Raab W (1983) Pharmakologie und Wirkungsmechanismus von Anthralin. Ärztl Kosmetol 13: 329–332

    CAS  Google Scholar 

  40. Rassner G (1972) Therapie der Psoriasis. Med Klin 67: 323

    PubMed  CAS  Google Scholar 

  41. Schaefer H, Schalla W, Shroot B (1981) Anthralin - facts, trends and unresolved problems. Zentralbl Haut Geschl Kr 146: 273 - 282

    Google Scholar 

  42. Swanbeck G, Lidén S (1966) The inhibitory effect of dithranol (anthralin) on DNA synthesis. Acta Derm Venereol (Stockh) 46: 228–230

    CAS  Google Scholar 

  43. Fisher LB, Maibach HI (1975) The effect of anthralin and its derivates on epidermal cell kinetics. J Invest Dermatol 64: 338–341

    Article  PubMed  CAS  Google Scholar 

  44. Saihan EM, Albano J, Burton JL (1980) The effect of steroid and dithranol therapy on cyclic nucleotides in psoriatic epidermis. Br J Dermatol 102: 565–569

    Article  PubMed  CAS  Google Scholar 

  45. Bedord CJ, Young JM, Wagner BM (1983) Anthralin inhibition of mouse epidermal arachidonic acid lipoxygenase in vitro. J Invest Dermatol 81 ¡566–571

    Google Scholar 

  46. Schröder JM, Kosfeld U, Christophers E (1984) Influence of anthralin, danthron and anthralin- dimer on neutrophil functions. Arch Dermatol Res 276: 265

    Google Scholar 

  47. Morhenn VB, Orenberg EK, Kaplan J, Pfendt E, Terrell C, Engleman EG (1983) Inhibition of a Langerhans cell-mediated immune response by treatment modalities useful in psoriasis. J Invest Dermatol 81: 23–27

    Article  PubMed  CAS  Google Scholar 

  48. Schaltegger A, Krebs A (1984) Oxidation behaviour of dithranol. Arch Dermatol Res 276: 274

    Google Scholar 

  49. Kammerau B, Zesch A, Schaefer H (1975) Absolute concentrations of dithranol and triacetyl- dithranol in the skin layers after local treatment: In vivo investigations with four different types of pharmaceutical vehicles. J Invest Dermatol 64: 145–149

    Google Scholar 

  50. Runne U, Kunze J (1982) Short-duration („minutes) therapy with dithranol for psoriasis: a new out-patient regimen. Br J Dermatol 106: 135–139

    Article  PubMed  CAS  Google Scholar 

  51. Steigleder GK, Pullmann H, Schulze HJ, Sterry W (1983) Kombinationsschemata zur Behandlung der Psoriasis. In: Braun-Falco O, Burg G (Hrsg) Fortschr prakt Dermatol Venerol, Bd 10. Springer, Berlin Heidelberg New York Tokyo, S 87–92

    Google Scholar 

  52. Christophers E, Reusch M (1983) Heutiger Stand der Photochemotherapie (PUVA). In: Braun- Falco O, Burg G (Hrsg) Fortschr prakt Dermatol Venerol, Bd 10. Springer, Berlin Heidelberg New York Tokyo, S 67–74

    Google Scholar 

  53. Niggli HJ, Cerutti PA (1982) Nucleosomal distribution of thymine photodimers following far- and near-ultraviolet light. Biochim Biophys Res Commun 105: 1215–1223

    Article  CAS  Google Scholar 

  54. Ben-Hur E, Elkind MM (1973) Psoralen plus near ultraviolet light inactivation of cultured Chinese hamster cells and its relation to DNA cross-links. Mutat Res 18: 315–324

    Article  PubMed  CAS  Google Scholar 

  55. Wiesehahn GP, Hyde JE, Hearst JE (1977) The photoaddition of trimethylpsoralen to Drosophila melanogaster nucleic acid: A probe for chromatin substructure. Biochemistry 16: 925–932

    Google Scholar 

  56. De Mol NJ, Reijersbergen van Henegouwen GM J (1979) Formation of singlet molecular oxygen by 8-methoxypsoralen. Photochem Photobiol 30: 331–335

    Article  CAS  Google Scholar 

  57. Mofti AM el (1948) A preliminary clinical report on the treatment of leucoderma with Ammi majus Linn. J Roy Egypt Med Ass 31: 651 - 665

    Google Scholar 

  58. Pathak MA, Fellman JH (1960) Activating and fluorescent wavelengths of furocoumarins: Psoralens. Nature 185: 382

    Google Scholar 

  59. Tronnier H, Schüle D (1973) Zur dermatologischen Therapie von Dermatosen mit langwelligem UV nach Photosensibilisierung der Haut mit Methoxsalen. Z Haut Geschl Kr 48: 385

    CAS  Google Scholar 

  60. Christophers E, Hönigsmann H, Wolff K, Langner A (1978) PUVA-treatment of urticaria pigmentosa. Br J Dermatol 98: 701–702

    Article  PubMed  CAS  Google Scholar 

  61. Wolff K, Fitzpatrick TB, Parrish JA, Gschnait F, Gilchrest B, Hönigsmann H, Pathak MA, Tanenbaum L (1976) Photochemotherapy for psoriasis with orally administered methoxsalen. Arch Dermatol 112: 943

    Article  PubMed  CAS  Google Scholar 

  62. Hofmann C, Plewig G, Braun-Falco O (1976) Photochemotherapie. Klinische Erfahrungen mit der 8-methoxypsoralen-UVA-Therapie ( Photochemotherapie) bei Psoriasis. Hautarzt 27: 588

    Google Scholar 

  63. Henseler T, Hönigsmann H, Wolff K, Christophers E (1981) Oral 8-methoxypsoralen photochemo¬therapy of psoriasis. Lancet 1: 853 — 857

    Article  PubMed  CAS  Google Scholar 

  64. Koch HR (1981) Augenschutz bei der Photochemotherapie. Aktuel Dermatol 7: 79

    Google Scholar 

  65. Fritsch PO, Hönigsmann H, Jaschke E, Wolff K (1978) Augmentation of oral methoxsalen - photochemotherapy with an oral retinoic acid derivative. J Invest Dermatol 70: 178–182

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatologische Klinik und Poliklinik, der Ludwig-Maximilians-Universität, Frauenlobstr. 9-11, D-8000, München 2, Germany

    Prof.Dr. med. Dr. phil. Johannes Ring

  2. Kneipp-Apotheke und Sebastian-Kneipp Zentral-Institut, Kneippstr. 2, D-8939, Bad Wörishofen, Germany

    Dr. rer. nat. Hans Horst Fröhlich

Authors
  1. Prof.Dr. med. Dr. phil. Johannes Ring
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. rer. nat. Hans Horst Fröhlich
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Ring, J., Fröhlich, H.H. (1985). Immunsuppressiva und Zytostatika. In: Wirkstoffe in der dermatologischen Therapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-70025-5_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-70025-5_16

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-13769-6

  • Online ISBN: 978-3-642-70025-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation